Volume 33, 1987, Numbers 1–3

CONTENTS

Number 1	PAGE
Mechanisms of monooxygenase induction and inhibition: *K. J. Netter*	1
Human drug metabolism polymorphisms: Use of recombinant DNA techniques: *D. W. Nebert and A. K. Jaiswal*	11
Mechanisms of phenobarbital-type induction of cytochrome P-450 isozymes: *R. Fonne and U. A. Meyer*	19
Induction and inhibition of conjugating enzymes with emphasis on UDP-glucuronyltransferases: *K. W. Bock, W. Lilienblum, G. Fischer, G. Schirmer and B. S. Bock-Hennig*	23
Coordinate induction of peroxisomal β-oxidation activity and cytosolic epoxide hydrolase activity: *F. Oesch and L. Schladt*	29
Importance of the glutathione cycle in drug metabolism: *P. Moldeus and Jiang Quanguan*	37
Formation of reactive intermediates and metabolites: Effects of macrolide antibiotics on cytochrome P-450: *D. Mansuy*	41
Metabolic characterization of human liver microsomal cytochromes P-450 involved in the oxidation of debrisoquine, bufuralol and the carcinogen 2-acetylaminofluorene: *M. E. McManus*	47
Developmental aspects of enzyme induction and inhibition: *W. Klinger*	55
Oxygen activation during drug metabolism: *V. V. Subrahmanyam, L. G. McGirr and P. J. O'Brien*	63
Methoxyphenamine *O*-demethylase and 5-hydroxylase: A GLC-ECD assay to study their activities and their inhibition by debrisoquine and sparteine: *E. M. Hawes, S. D. Roy, G. McKay and K. K. Midha*	73
Stereospecificity of enzyme induction by 2-phenylpropionic acid: *S. Fournel, J. Caldwell, J. Magdalou and G. Siest*	79
Prevention of acetaminophen hepatotoxicity by disulfiram: *H. E. Poulsen, L. Jorgensen and P. Thomsen*	83
Reversible inhibition and activation of hepatic GSH *S*-transferases by ethylene dibromide: *K. M. Ivanetich and A. E. A. Thumser*	85
Induction and its influence on human cancer: *H. Remmer*	89
Enzyme induction in humans, clinical aspects—An overview: *A. Breckenridge*	95
In vitro studies of induction and inhibition of drug oxidation in man: *A. R. Boobis, S. Murray, C. E. Seddon and D. S. Davies*	101
In vivo methods to study enzyme induction and enzyme inhibition: *B. K. Park*	109
Environmental factors of enzyme induction and inhibition: *O. Pelkonen and E. A. Sotaniemi*	115
Ethanol as enzyme inducer and inhibitor: *H. Hoensch*	121
H_2-receptor antagonists as inhibitors of oxidative drug metabolism *in vivo*: *W. Kirch*	129
Drugs other than H_2-receptor antagonists as clinically important inhibitors of drug metabolism *in vivo*: *R. Gugler and J. C. Jensen*	133

Clinical implications of hepatic microsomal enzyme induction by antiepileptic drugs: *E. Perucca* 139
Aminoglutethimide as an inducer of oxidative drug metabolism in the rat: *Z. Damanhouri, S. A. Herbert and P. J. Nicholls* 145
Therapeutic use of phenobarbital in intrahepatic cholestasis. Inductions in bile acid metabolism: *P. Back* 153
Comparative effects of H_2-receptor antagonists on drug metabolism *in vitro* and *in vivo*: *U. Klotz, P. Arvela, M. Pasanen, H. Kroemer and O. Pelkonen* 157
Influence of mexiletine on caffeine elimination: *R. Joeres, H. Klinker, H. Heusler, J. Epping and E. Richter* 163
The influence of ethanol on cyclophosphamide pharmacokinetics and metabolism in tumor-bearing rats: *E. A. De Bruijn, A. T. Van Oosterom and U. R. Tjaden* 171
Hydroperoxide metabolism in vitamin E-deficient hepatocytes. Studies on low-level chemiluminescence, lipid peroxidation, and glutathione status: *F. J. Romero and E. Cadenas* 179
Aminopyrine *N*-demethylation in young, old and tumour bearing B6C3 F1 mice: *D. A. Smith* 187
Increased cyt P-450 dependent function in healthy HB$_s$Ag carriers: *A. P. Geubel, S. Pauwels, J. P. Buchet, E. Dumont and C. Dive* 193
The urinary 6β-hydroxycortisol excretion in man on inducers and inhibitors of the hepatic mixed function oxidase: *J. P. Desager, E. Dumont and C. Harvengt* 197
Influence of the enzyme induction by rifampicin on its presystemic metabolism: *U. Loos, E. Musch, J. C. Jensen, H. K. Schwabe and M. Eichelbaum* 201
Enzyme induction of renal transport mechanism by rifampicin in man? *N. H. Brockmeyer, H. Heidemann and E. E. Ohnhaus* 205

Numbers 2/3

Oxytocin and vasopressin: Photoaffinity labeling of neurophysins, secretory granule hormone-binding proteins: *D. M. Abercrombie and I. M. Chaiken* 209
Inhibitors of protein glycosylation and glycoprotein processing in viral systems: *R. Datema, S. Olofsson and P. A. Romero* 221
Photoaffinity labelling of the adenosine nucleotide transporter of cholinergic vesicles: *V. Witzemann* 287
Selenium effects on drug and foreign compound toxicity: *G. F. Combs Jr and S. B. Combs* 303
Photoaffinity labeling of thyroid hormone receptors: *Z. D. Horowitz and H. H. Samuels* 317
Photoaffinity labelling of *N*-formyl peptide receptors: *R. A. Allen, A. J. Jesaitis and C. G. Cochrane* 333
Photoaffinity labelling of angiotensin receptors: Functional studies on responding tissues: *G. J. Moore* 349
Clinical pharmacology of non-steroidal anti-inflammatory drugs: *R. O. Day, G. G. Graham, K. M. Williams, G. D. Champion and J. de Jager* 383
Ethanol and minerals: *J. D. Blachley and J. P. Knochel* 435
Occurrence and treatment of solvent abuse in children and adolescents: *H. G. Morton* 449